Yves Daniel Compaoré

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Mehreen S. Datoo, Alassane Dicko, Halidou Tinto et al. · The Lancet · 2024 · 296 citations · Full text

Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial

Issaka Sagara, Abdoul Habib Béavogui, Issaka Zongo et al. · The Lancet · 2018 · 133 citations · Full text

Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso

Issaka Zongo, Paul Milligan, Yves Daniel Compaoré et al. · Antimicrobial Agents and Chemotherapy · 2015 · 86 citations · Full text

Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial

Issaka Sagara, Abdoul Habib Béavogui, Issaka Zongo et al. · The Lancet Infectious Diseases · 2015 · 81 citations · Full text

Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso

Anyirékun Fabrice Somé, Issaka Zongo, Yves Daniel Compaoré et al. · Antimicrobial Agents and Chemotherapy · 2014 · 55 citations · Full text

Seasonal Malaria Chemoprevention, Drug Resistance Analysis, Burkina Faso +14